Lipopolysaccharide degradation

The term "Lipopolysaccharide degradation" does not refer to a single molecule, receptor, or canonical therapeutic target. Instead, it describes a *biochemical process* involving the breakdown of lipopolysaccharide (LPS), a major component of the outer membrane of Gram-negative bacteria[5][6][8]. LPS degradation can involve multiple enzymes (such as acyloxyacyl hydrolase and intestinal alkaline phosphatase) and sometimes can be catalyzed by exogenous factors, including certain nanoparticles or reactive oxygen species[3][5]. LPS itself is recognized by the immune system through complexes such as TLR4/MD2/CD14, but these are not implicated in its "degradation"; rather, they sense intact LPS leading to immune responses and inflammation[5][6]. Therefore, "Lipopolysaccharide degradation" is not a recommended canonical name for a therapeutic target. If the intention is to refer to a specific LPS-degrading enzyme or pathway (e.g., acyloxyacyl hydrolase), the query should specify that molecule or enzyme.